ESR1 and breast carcinoma: Although more studies are needed to demonstrate the ERα/β heterodimer as a therapeutic target, the concept of inducing ERβ to pair with ERα, thus antagonizing ERα's proliferative function, is distinct from existing breast cancer therapeutic strategies of targeting ERα alone.